Next generation prophylactic human papillomavirus vaccines

The Lancet Oncology

Volumn 16, Issue 5, 2015, Pages e217-e225

  Schiller, John T ^a   Müller, Martin ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; HYBRID PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 6; VIRUS LIKE PARTICLE VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; CANCER SCREENING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; GENE TARGETING; HUMAN; IMMUNOGENICITY; MEASLES; PRIORITY JOURNAL; PROPHYLAXIS; REGULATORY T LYMPHOCYTE; REVIEW; SCHOOL CHILD; TYPHOID FEVER; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VACCINE PRODUCTION; VIRION; COST BENEFIT ANALYSIS; FEMALE; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOLOGY; PATHOGENICITY; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

ADOLESCENT; CAPSID PROTEINS; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84933501571     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71179-9     Document Type: Review

References (72)

1. Stanley M, Pinto LA, Trimble C Human papillomavirus vaccines-immune responses. Vaccine 2012, 30(suppl 5):F83-F87.
2. Schiller JT, Lowy DR Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012, 10:681-692.
3. Schiller JT, Castellsagué X, Garland SM A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(suppl 5):F123-F138.
4. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013, 346:f2032.
5. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011, 377:2085-2092.
6. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013, 32:26-32.
7. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014, 14:958-966.
8. Macartney KK, Chiu C, Georgousakis M, Brotherton JM Safety of human papillomavirus vaccines: a review. Drug Saf 2013, 36:393-412.
9. Hopkins TG, Wood N Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes. Vaccine 2013, 31:1673-1679.
10. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 2013, 62:591-595. Centers for Disease Control and Prevention (CDC).
11. GAVI injects new life into HPV vaccine rollout. Lancet 2013, 381:1688. The Lancet.
12. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007, 298:743-753. the Costa Rican HPV Vaccine Trial Group.
13. Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 2010, 28:671-678.
14. Jadhav S, Gautam M, Gairola S Role of vaccine manufacturers in developing countries towards global healthcare by proving quality vaccines at affordable prices. Clin Microbiol Infect 2014, 20(suppl 5):37-44.
15. Krajden M, Cook D, Yu A, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol 2011, 18:418-423.
16. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
17. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007, 196:1153-1162.
18. EPAR summary for the public: Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted adsorbed) European Medicins Agency, (accessed April 2, 2015). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf.
19. Übertragbare krankheiten-HPV vaccination: from the 3-dose to the 2-dose schedule among young people under 15 years Federal Office of Public Health Directorate Public Health Division of Communicable Diseases, (accessed April 2, 2015). http://www.bag.admin.ch/impfinformation/06318/index.html?lang=de&download=NHzLpZig7t,lnp6I0NTU042l2Z6ln1acy4Zn4Z2qZpnO2Yuq2Z6gpJCKeX52g2ym162dpYbUzd,Gpd6emK2Oz9aGodetmqaN19XI2IdvoaCUZ,s-.
20. Final report of the XXI Technical Advisory Group (TAG) meeting on vaccine-preventable diseases of the Pan American Health Organization Pan American Health Organization Technical Advisory Group, (accessed April 2, 2015). http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&Itemid=&gid=26691&lang=en.
21. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451. the CVT Vaccine Group.
22. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6:1242-1250. the CVT Group.
23. Garçon N, Wettendorff M, Van Mechelen M Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011, 11:667-677.
24. Stanley M, Gissmann L, Nardelli-Haefliger D Immunobiology of human papillomavirus infection and vaccination-implications for second generation vaccines. Vaccine 2008, 26(suppl 10):K62-K67.
25. Cuburu N, Kweon MN, Hervouet C, et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009, 183:7851-7859.
26. Nardelli-Haefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005, 23:3634-3641.
27. Corbett HJ, Fernando GJ, Chen X, Frazer IH, Kendall MA Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One 2010, 5:e13460.
28. Ding DC, Chang YC, Liu HW, Chu TY Long-term persistence of human papillomavirus in environments. Gynecol Oncol 2011, 121:148-151.
29. Noronha AS, Markowitz LE, Dunne EF Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014, 32:2670-2674.
30. HPV vaccine works against nine viral types. Cancer Discov 2014, 4:OF2. Cancer Discovery.
31. Inglis S, Shaw A, Koenig S Chapter 11: HPV vaccines: commercial research & development. Vaccine 2006, 24(suppl 3):99-105.
32. Zhao H, Lin ZJ, Huang SJ, et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Hum Vaccin Immunother 2014, 10:740-746.
33. Hu YM, Huang SJ, Chu K, et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. Hum Vaccin Immunother 2014, 10:469-475.
34. Gersch ED, Gissmann L, Garcea RL New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antivir Ther 2012, 17:425-434.
35. Schädlich L, Senger T, Gerlach B, et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 2009, 83:7690-7705.
36. Thönes N, Herreiner A, Schädlich L, Piuko K, Müller M A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 2008, 82:5472-5485.
37. Bazan SB, de Alencar Muniz Chaves A, Aires KA, Cianciarullo AM, Garcea RL, Ho PL Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol 2009, 154:1609-1617.
38. Hanumantha Rao N, Baji Babu P, Rajendra L, et al. Expression of codon optimized major capsid protein (L1) of human papillomavirus type 16 and 18 in Pichia pastoris; purification and characterization of the virus-like particles. Vaccine 2011, 29:7326-7334.
39. Giorgi C, Franconi R, Rybicki EP Human papillomavirus vaccines in plants. Expert Rev Vaccines 2010, 9:913-924.
40. Cantarella G, Liniger M, Zuniga A, et al. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009, 27:3385-3390.
41. Lee HJ, Park N, Cho HJ, et al. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 2010, 28:1613-1619.
42. Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum Gene Ther 2012, 23:733-741.
43. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007, 14:1285-1295.
44. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010, 8:260-270.
45. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005, 337:365-372.
46. Karanam B, Jagu S, Huh WK, Roden RB Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009, 87:287-299.
47. Schellenbacher C, Kwak K, Fink D, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol 2013, 133:2706-2713.
48. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012, 19:1075-1082.
49. Jagu S, Kwak K, Karanam B, et al. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 2013, 8:e55538.
50. Amanna IJ, Slifka MK Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, 236:125-138.
51. Nieto K, Weghofer M, Sehr P, et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 2012, 7:e39741.
52. Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One 2012, 7:e49751.
53. Yoon SW, Lee TY, Kim SJ, et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine 2012, 30:3286-3294.
54. Tumban E, Peabody J, Peabody DS, Chackerian B A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants. Vaccine 2013, 31:4647-4654.
55. Rubio I, Bolchi A, Moretto N, et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 2009, 27:1949-1956.
56. Kalnin K, Tibbitts T, Yan Y, et al. Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes. Vaccine 2014, 32:3540-3547.
57. Alphs HH, Gambhira R, Karanam B, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008, 105:5850-5855.
58. Seitz H, Dantheny T, Burkart F, Ottonello S, Müller M Influence of oxidation and multimerization on the immunogenicity of a thioredoxin-l2 prophylactic papillomavirus vaccine. Clin Vaccine Immunol 2013, 20:1061-1069.
59. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927. FUTURE II Study Group.
60. Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012, 344:e1401. the FUTURE I and II Study Group.
61. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007, 13:857-861.
62. Ma B, Maraj B, Tran NP, et al. Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs 2012, 17:469-492.
63. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009, 361:1838-1847.
64. Nieto K, Gissmann L, Schädlich L Human papillomavirus-specific immune therapy: failure and hope. Antivir Ther 2010, 15:951-957.
65. Müller M, Zhou J, Reed TD, et al. Chimeric papillomavirus-like particles. Virology 1997, 234:93-111.
66. Greenstone HL, Nieland JD, de Visser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998, 95:1800-1805.
67. Peng S, Frazer IH, Fernando GJ, Zhou J Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998, 240:147-157.
68. Kaufmann AM, Nieland JD, Jochmus I, et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121:2794-2800.
69. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010, 102:1129-1136.
70. Karanam B, Gambhira R, Peng S, et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 2009, 27:1040-1049.
71. Bharati K, Ganguly NK Does India need an indigenous HPV vaccine and why?. J Public Health Policy 2013, 34:272-287.
72. Schiller JT, Lowy DR Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009, 200:166-171.